뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 0.25mg (exclusive of 1.5% excess.);  ;   - tablet - 0.25 mg - active: alprazolam 0.25mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide [docusate sodium (85% ) with sodium benzoate [15%] lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 0.5mg (exclusive of 1.5% excess.);  ;   - tablet - 0.5 mg - active: alprazolam 0.5mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide docusate sodium erythrosine lactose monohydrate magnesium stearate maize starch microcrystalline cellulose sodium benzoate - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 1mg (exclusive of 1.5% excess.);  ;   - tablet - 1 mg - active: alprazolam 1mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide erythrosine indigo carmine docusate sodium (85%) with sodium benzoate (15%) lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

말레이시아 - 영어 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

viatris sdn. bhd. - alprazolam -

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - alprazolam - tablet - 1 milligram(s) - benzodiazepine derivatives; alprazolam

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - alprazolam - tablet - 500 microgram(s) - benzodiazepine derivatives; alprazolam

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - alprazolam - tablet - 250 microgram(s) - benzodiazepine derivatives; alprazolam

싱가포르 - 영어 - HSA (Health Sciences Authority)

viatris private limited - alprazolam - tablet, sugar coated - 0.5 mg - alprazolam 0.5 mg

싱가포르 - 영어 - HSA (Health Sciences Authority)

viatris private limited - alprazolam - tablet, sugar coated - 1 mg - alprazolam 1 mg

싱가포르 - 영어 - HSA (Health Sciences Authority)

pfizer pfe private limited - alprazolam - tablet, sugar coated - 2 mg - alprazolam 2 mg